LitAlert ~~ GeneLit.com

    • Genomic, Transcriptomic, and Functional Alterations in DNA Damage Response Pathways as Putative Biomarkers of Chemotherapy Response in Ovarian Cancer.
    • Sharma Saha A, Gentles L, Bradbury A, Brecht D, Robinson R, O’Donnell R, Curtin NJ, Drew Y.
    • Cancers (Basel). 2021 Mar 20;13(6):E1420. doi: 10.3390/cancers13061420.
    • Structural variants at the BRCA1/2 loci are a common source of homologous repair deficiency in high grade serous ovarian carcinoma.
    • Ewing A, Meynert A, Churchman M, Grimes G, Hollis RL, Herrington CS, Rye T, Bartos C, Croy I, Ferguson MJ, Lennie M, McGoldrick T, McPhail N, Siddiqui N, Dowson S, Glasspool R, Mackean M, Nussey F, McDade B, Ennis D, Genomes Partnership TS, McMahon L, Matakidou A, Dougherty BA, March R, Barrett JC, McNeish IA, Biankin AV, Roxburgh P, Gourley C, Semple CA.
    • Clin Cancer Res. 2021 Mar 19:clincanres.CCR-20-4068-A.2020. doi: 10.1158/1078-0432.CCR-20-4068. Epub ahead of print.
    • Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2.
    • Konecny GE, Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, Ray-Coquard I, Aghajanian C, Coleman RL, O'Malley DM, Leary A, Chen L, Provencher D, Ma L, Brenton JD, Castro C, Green M, Simmons AD, Beltman J, Harding T, Lin KK, Goble S, Maloney L, Kristeleit RS, McNeish IA, Swisher EM, Xiao JJ.
    • Gynecol Oncol. 2021 Mar 19:S0090-8258(21)00235-3. doi: 10.1016/j.ygyno.2021.03.015. Epub ahead of print.
    • NICE Recommends Lynparza, Avastin Combination in Ovarian Cancer Through Cancer Drugs Fund.
    • [No author given]
    • Precision Oncology News. Business & Policy. 2021 Mar 19.